Figure 1.

Patients with metastatic colorectal cancer with either standard KRAS testing (exon 2) versus expanded testing (KRAS exon 2, 3, 4; NRAS exon 2, 3, 4). Figure shows the different distribution of mutated versus wild type tumors based on type of testing with associated cost of the test and the EGFR inhibitor. The scenario in this figure is that the standard testing cost was $197 and the expanded testing cost was 30 times that amount, or $5,910. The total costs of getting cetuximab or panitumumab include the cost of the drug and the test.

Abbreviations: C, cetuximab; mCRC, metastatic colorectal cancer; P, panitumumab; WT, wild type.